Skip to content
-
Oncoinvent presents first half 2026 results
-
Invitation to First-Half 2026 webcast – Thursday 27 August 2026
-
Oncoinvent announces publication of normal tissue dosimetry results in Journal of Nuclear Medicine
-
Oncoinvent achieves 50% recruitment milestone in Phase 2 ovarian cancer study of Radspherin[®]
-
Oncoinvent ASA: Grant of share options to member of the Board following AGM
-
Oncoinvent ASA: Minutes from Annual General Meeting
-
Oncoinvent ASA: Share capital decrease completed
-
Oncoinvent presents corporate update in live webcast
-
Oncoinvent ASA: Notice of Annual General Meeting
